SK Biopharmaceuticals prices at top of range for S Korea's biggest IPO in 3 yrs


Drugmaker SK Biopharmaceuticals Co Ltd priced its initial public offering on Friday at the top of its indicative range, aiming to raise 959 billion won ($794 million) in South Korea’s biggest IPO in three years.

SK Biopharmaceuticals in November became the first South Korean company to receive U.S. Food and Drug Administration approval for an independently developed drug, called Xcopri, which is a treatment for epilepsy.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter